WASHINGTON, D.C.—Prostate cancer gene 3 (PCA3) may be a valuable predictor of pathologically confirmed low volume disease and insignificant prostate cancer (PCa), according to a study presented at the 2011 annual meeting of the American Urological Association.
WASHINGTON, D.C.—The FDA has approved the first and only testosterone therapy applied to the underarm.
WASHINGTON, D.C.—The rate of office-based PSA testing by primary care providers (PCPs) in the United States doubled from 1997 to 2008, according to data presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Obese men are less likely to have an abnormal digital rectal examination (DRE) than non-obese men, according to findings presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Elderly men who are overweight or obese are at increased risk for developing lower urinary tract symptoms (LUTS), but those who engage in a relatively high level of physical activity or daily walking for exercise have a reduced risk, data show.
WASHINGTON, D.C.—Severe adverse outcomes of benign prostatic hyperplasia (BPH) persist despite widespread use of oral therapies, according to a study presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Trigonal intradetrusor injections of botulinum toxin-A (BTX-A) results in greater reduction in overactive bladder (OAB) symptoms compared with trigone-sparing BTX-A injections, Irish investigators reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Statin use by hyperlipidemic patients may decrease the risk of urinary stone formation, according to study findings presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Silodosin may be an effective treatment for moderate or severe chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), researchers reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Adjuvant use of tamsulosin or nifedipine after extracorporeal shock wave lithotripsy (SWL) improves stone free rates in patients treated for non-lower pole renal stones 10-20 mm in diameter, Brazilian researchers reported at the American Urological Association 2011 annual meeting.
Please login or register first to view this content.
